CA-KONG
8.2.2021 16:32:14 CET | Business Wire | Press release
Kong Inc ., the cloud connectivity company, today announced it has closed $100 million in Series D funding, led by Tiger Global Management with participation from existing investors Index Ventures, CRV, GGV Capital and Andreessen Horowitz as well as new investor Goldman Sachs. This latest round brings Kong’s total funding to $171 million, tripling its valuation to $1.4 billion since the Series C round. Kong will use the capital to scale its go-to-market operations, grow world-class Engineering and Customer Experience teams, and accelerate cloud connectivity with its new SaaS-based Kong Konnect service connectivity platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005517/en/
“The shift to digital and cloud has been revolutionary across all fronts, quickly propelling developer-led organizations and API-first companies to the forefront,” said John Curtius, partner at Tiger Global Management. “With impressive momentum, happy customers and strong market share, Kong is primed to help organizations meet the growing demands of this new digital reality and succeed in today’s cloud native world. We have been following the company closely for the past couple of years, and Kong is really starting to pull away from the rest of the pack.”
The fundraise follows a record year for Kong, marked by a significant increase in adoption of its flagship open source software – Kong Gateway – now exceeding 220 million total downloads and 1.5 million monthly active instances. The company added key Global 2000 companies such as Deutsche Telekom, Orange, Papa John’s and Siemens to its growing enterprise customer base, as well as tripled its small business and mid-market enterprise customers. In addition, Kong was recognized as an Inc. 5000 company and a Deloitte Technology Fast 500 company with 1,908% revenue growth over a three-year period.
“In 2020, we saw an explosion of data in motion and services as companies fast-tracked the release of new digital experiences in response to the pandemic,” said Augusto Marietti, CEO and co-founder of Kong Inc. “Software is truly becoming like a giant nervous system through millions of APIs and services. Kong is on a mission to become the spinal cord and backbone by building the cloud connectivity fabric of the future.”
IDC predicts that worldwide data will reach 175 zettabytes by 2025, with 49% of the data residing in the cloud. According to Gartner, cloud native platforms will serve as the foundation for more than three-quarters of new digital workloads by 2024. Kong Konnect, a full-stack service connectivity platform designed for cloud native applications and delivered as a service, enables developers, architects and operators to seamlessly deliver connectivity at the edge, within their applications and between applications. It provides universal service connectivity and management that is reliable, observable and secure across any infrastructure.
“Modern infrastructure is driven by open source technologies, and Kong’s open source DNA has played a pivotal role in driving its adoption both in the community and in enterprise organizations,” said Marco Palladino, CTO and co-founder of Kong Inc. “Kong Konnect takes cloud connectivity to the next level by providing a full-stack service connectivity platform that goes from API gateways to services meshes via open technologies like Kong Gateway, CNCF’s Kuma and Insomnia – running across every cloud and every platform, including on Kubernetes and VMs. Teams around the world can now abstract away their enterprise L4-L7 connectivity in one click to build secure, resilient and distributed applications like never before.”
Additional Resources
About Kong Inc.
Kong creates software and managed services that connect APIs and microservices natively across and within clouds, Kubernetes, data centers and more using intelligent automation. Built on an open source core, Kong’s service connectivity platform enables digital innovation by allowing organizations to reliably and securely manage the full lifecycle of APIs and services for modern architectures, including microservices, serverless and service mesh. By providing developer teams with unprecedented architectural freedom, Kong accelerates innovation cycles, increases productivity, and seamlessly bridges legacy and modern systems and applications. For more information about Kong, please visit https://konghq.com or follow @thekonginc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom